Publicacions<\/h2>\n\t\t\t\t![\"112-sarcoma-omteztirado-def\"](\"https:\/\/idibell.cat\/wp-content\/uploads\/2020\/04\/112-sarcoma-omteztirado-def.jpg\" "\\"112-sarcoma-omteztirado-def\\"")
\n\t\t\t\t\tL\u00ednies estrat\u00e8giques<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tIdentificaci\u00f3 dels actors metast\u00e0tics i estudi del seu paper biol\u00f2gic en els sarcomes del desenvolupament.
\nIdentificaci\u00f3 de noves dianes terap\u00e8utiques i avaluaci\u00f3 precl\u00ednica de nous compostos per al tractament de sarcomes (Xavier Garc\u00eda del Muro)
\nIdentificaci\u00f3 de nous marcadors pron\u00f2stics per als sarcomes (Xavier Garc\u00eda del Muro)\n\t\t\t\t\tPublicacions seleccionades<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tCasali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Buonadonna A, De Alava E, Dei Tos AP, del Muro XG, Dufresne A, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kasper B, Kawai A, Kopeckova K, Krakorova DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez Pousa A, Martin Broto J, Merimsky O, Messiou C, Miah AB, Mir O, Montemurro M, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schoffski P, Sleijfer S, Strauss D, Strauss SJ, Hall KS, Trama A, Unk M, van de Sande M, van der Graaf W, van Houdt WJ, Frebourg T, Gronchi A, Stacchiotti S, ESMO Guidelines C, E, G. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up<\/strong>. Ann. Oncol. 2022;33(1):20-33. doi:10.1016\/j.annonc.2021.09.005.<\/p>\nGounder MM, Razak AA, Somaiah N, Chawla S, Martin Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gr\u00f6schel S, Hatcher H, Duffaud F, Herr\u00e1ez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, G\u00f6tze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial<\/strong>. J. Clin. Oncol. 2022;40(22):2479-2490. doi:10.1200\/JCO.21.01829.<\/p>\nArchilla Ortega A, Domuro C, Martin Liberal J, Mu\u00f1oz P. Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity<\/strong>. J. Exp. Clin. Cancer Res. 2022;41(1):62-62. doi:10.1186\/s13046-022-02264-x.<\/p>\nPascual Pasto G, Castillo Ecija H, Unceta N, Aschero R, Resa Pares C, G\u00f3mez Caballero A, Vila Ubach M, Mu\u00f1oz Aznar O, Su\u00f1ol M, Burgue\u00f1o V, Gomez Gonzalez S, Sosnik A, Ibarra M, Schaiquevich P, de \u00c1lava E, Tirado OM, Mora J, Carcaboso AM. SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas<\/strong>. J Control Release. 2022;34281-92. doi:10.1016\/j.jconrel.2021.12.035.<\/p>\nGarc\u00eda Dom\u00ednguez DJ, Hajji N, L\u00f3pez Alemany R, S\u00e1nchez Molina S, Figuerola Bou E, Mor\u00f3n Civanto FJ, Rello Varona S, Andr\u00e9s Le\u00f3n E, Benito A, Keun HC, Mora J, Tirado \u00d3M, de \u00c1lava E, Hontecillas Prieto L. Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1<\/strong>. Oncogene. 2022;41(18):2638-2650. doi:10.1038\/s41388-022-02279-w.<\/p>\n\t\t\t\t\tProjectes seleccionats<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tFIS21126. TILS TREATMENT IN ADVANCED TUMORS WITH ALTERATIONS IN THE SWI\/SNF COMPLEX: THE TILTS STUDY<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 1081914,72. 2022-2025. PI: Mart\u00edn Liberal, Juan.<\/p>\n20MAR001. Molecular analysis of the metastatic process in developmental tumors. Fundaci\u00f3 TV3<\/strong>. Budget: 300000. 2020-2023. PI: MARTINEZ TIRADO, OSCAR.<\/p>\n19ACL231. ESTUDIO DE FASE 1B\/2 DE LY3200882 Y PEMBROLIZUMAB EN PACIENTES CON C\u00c1NCER AVANZADO<\/strong>. Budget: 267326,4. 2019- . PI: Mart\u00edn Liberal, Juan.<\/p>\n2021-070-1. PROSPECTIVE COLLECTION OF DONOR TISSUE AND WHOLE BLOOD OR LEUKAPHERESIS PRODUCT FROM PATIENTS WITH SOLID TUMOURS TO ENABLE DEVELOPMENT OF METHODS FOR THE MANUFACTURING OF CLONAL NEOANTIGEN T CELL PRODUCTS (cNeT). ACHILLES THERAPEUTICS UK LIMITED<\/strong>. Budget: 220881,12. 2021- . PI: Mart\u00edn Liberal, Juan.<\/p>\n20ACL101. A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH – 1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA. REGENERON PHARMACEUTICAL, INC<\/strong>. Budget: 203366,88. 2020- . PI: Mart\u00edn Liberal, Juan.<\/p>\n\t\t\t\t\tTransfer\u00e8ncia de tecnologia<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tPAT064-EPH2A APTAMER AND USES THEREOF
\nIP: Oscar Mart\u00ednez tirado
\nEP19382451\nLicense: EPH2A APTAMER AND USES THEREOF
\nPI: Dr. \u00d3scar Mart\u00ednez-Tirado\nSpin-off: Aptadel Therapeutics
\nPI: Dr. \u00d3scar Mart\u00ednez-Tirado\n\t\t\t\t\tM\u00e9s informaci\u00f3<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tDesenvolupament d’un nou model ortot\u00f2pic per estudiar la met\u00e0stasi del sarcoma
\nDescripci\u00f3 del metiloma del sarcoma d’Ewing\n\t\t\t\t![\"Oscar-Martinez-Tirado\"](\"https:\/\/idibell.cat\/wp-content\/uploads\/2020\/11\/Oscar-Martinez-Tirado-150x150.jpg\" "\\"Oscar-Martinez-Tirado\\"")
\n\n\t\tMartinez Tirado, Oscar\n\t<\/h4>\n\n\t\t\n\t\tomartinez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\n\t\tInvestigadors principals\n\t<\/h2>\n\t\t\t\t\n\n\t\tMartinez Tirado, Oscar\n\t<\/h4>\n\n\t\t\n\t\tomartinez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t![\"Xavier-Garcia-del-Muro\"](\"https:\/\/idibell.cat\/wp-content\/uploads\/2020\/11\/Xavier-Garcia-del-Muro-150x150.jpg\" "\\"Xavier-Garcia-del-Muro\\"")
\n\n\t\tGarc\u00eda del Muro, Solans Xavier\n\t<\/h4>\n\n\t\t\n\t\tgarciadelmuro@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\n\t\tENLLA\u00c7OS RELACIONATS\n\t<\/h4>\n\n\t\t\n\t\tFacebook\n\t\t<\/a>\n\t<\/h4>\n\n\t\t\n\t\t@SRGIDIBELL\n\t\t<\/a>\n\t<\/h4>\n\n\t\t\n\t\t@omt2007\n\t\t<\/a>\n\t<\/h4>\n\n\t\tEquip\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tCaps de grup\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es principals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es cl\u00ednics\/ques\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es postdoctorals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es predoctorals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tSuport cient\u00edfic\t\t\t\t<\/a>\n\t\t\t\t\t\tCaps de grup\n\t\t\t\t\t\t\t\t\t\t\t\n- Martinez Tirado, Oscar<\/li>\n<\/ul>\n\t\t\t\t\t\tInvestigadors\/es principals\n\t\t\t\t\t\t\t\t\t\t\t
\n- Garc\u00eda del Muro, Solans Xavier<\/li>\n<\/ul>\n\t\t\t\t\t\tInvestigadors\/es cl\u00ednics\/ques\n\t\t\t\t\t\t\t\t\t\t\t
\n- Sanjuan Garriga, Francesc Xavier<\/li>\n<\/ul>\n\t\t\t\t\t\tInvestigadors\/es postdoctorals\n\t\t\t\t\t\t\t\t\t\t\t
\n- Chic\u00f3n Bosch, Mariona<\/li>\n<\/ul>\n\t\t\t\t\t\tInvestigadors\/es predoctorals\n\t\t\t\t\t\t\t\t\t\t\t
\n- Sanchez Serra, Sara<\/li>\n<\/ul>\n\t\t\t\t\t\tSuport cient\u00edfic\n\t\t\t\t\t\t\t\t\t\t\t
\n- L\u00f3pez Alemany, Roser<\/li>\n
- Gris Lorente, Manuel<\/li>\n
- Rosas Lape\u00f1a, Marta<\/li>\n<\/ul>\n
\n\t\tNot\u00edcies relacionades\n\t<\/h2>\n\t\t\n\t\t\t\t<\/a>\n\t\t\tL’IDIBELL i la Universitat de Iowa desenvolupen una nova mol\u00e8cula per al tractament dirigit contra el c\u00e0ncer<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t30\/05\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tL’IDIBELL rep 1,2 milions d’euros en ajuts per impulsar la recerca cient\u00edfica i la seva transfer\u00e8ncia<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t10\/01\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tLa inhibici\u00f3 farmacol\u00f2gica d’una prote\u00efna redueix les met\u00e0stasis en models in vivo i in vitro de sarcoma d’Ewing<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t01\/04\/2022\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tLa spin-off sorgida de l’IDIBELL Aptadel seleccionada per formar part de BCN Health Booster<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t26\/11\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tUn nou algoritme classifica els tipus de sarcoma<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t02\/02\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tAptadel, nova spinoff de l’IDIBELL<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t22\/01\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL celebra el Kickoff Meeting dels projectes finan\u00e7ats per La Fundaci\u00f3 La Marat\u00f3 de TV3 2019<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t18\/11\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tEl grup de recerca en sarcoma de l’IDIBELL rebr\u00e0 una de les noves ajudes AECC Innova<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t10\/09\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIdentifiquen una prote\u00efna determinant per a la progressi\u00f3 tumoral i la met\u00e0stasi del c\u00e0ncer infantil Rabdomiosarcoma<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t29\/01\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tL’IDIBELL i la Fundaci\u00f3n Alba P\u00e9rez fan un nou pas endavant per desenvolupar un tractament per al sarcoma d’Ewing<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t03\/12\/2019\t\t\t\t\t\t\t\n\t\t\n\n","protected":false},"excerpt":{"rendered":"Sarcoma Resum El grup de recerca en sarcomes, liderat per l\u00b4\u00d2scar Martinez-Tirado, \u00e9s un grup multidisciplinar amb els objectius principals d’ identificar nous marcadors metast\u00e0tics i aprofundir en el seu paper biol\u00f2gic en sarcomes del desenvolupament, i identificar nous objectius terap\u00e8utics i validar nous marcadors pron\u00f2stics i predictius en sarcomes, avaluant precl\u00ednicament nous components per […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"publishpress_future_action":{"enabled":false,"date":"2024-05-13 00:53:06","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/1807"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=1807"}],"version-history":[{"count":5,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/1807\/revisions"}],"predecessor-version":[{"id":24866,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/1807\/revisions\/24866"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=1807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Gounder MM, Razak AA, Somaiah N, Chawla S, Martin Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gr\u00f6schel S, Hatcher H, Duffaud F, Herr\u00e1ez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, G\u00f6tze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial<\/strong>. J. Clin. Oncol. 2022;40(22):2479-2490. doi:10.1200\/JCO.21.01829.<\/p>\n Archilla Ortega A, Domuro C, Martin Liberal J, Mu\u00f1oz P. Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity<\/strong>. J. Exp. Clin. Cancer Res. 2022;41(1):62-62. doi:10.1186\/s13046-022-02264-x.<\/p>\n Pascual Pasto G, Castillo Ecija H, Unceta N, Aschero R, Resa Pares C, G\u00f3mez Caballero A, Vila Ubach M, Mu\u00f1oz Aznar O, Su\u00f1ol M, Burgue\u00f1o V, Gomez Gonzalez S, Sosnik A, Ibarra M, Schaiquevich P, de \u00c1lava E, Tirado OM, Mora J, Carcaboso AM. SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas<\/strong>. J Control Release. 2022;34281-92. doi:10.1016\/j.jconrel.2021.12.035.<\/p>\n Garc\u00eda Dom\u00ednguez DJ, Hajji N, L\u00f3pez Alemany R, S\u00e1nchez Molina S, Figuerola Bou E, Mor\u00f3n Civanto FJ, Rello Varona S, Andr\u00e9s Le\u00f3n E, Benito A, Keun HC, Mora J, Tirado \u00d3M, de \u00c1lava E, Hontecillas Prieto L. Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1<\/strong>. Oncogene. 2022;41(18):2638-2650. doi:10.1038\/s41388-022-02279-w.<\/p>\n\t\t\t\t\tProjectes seleccionats<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t FIS21126. TILS TREATMENT IN ADVANCED TUMORS WITH ALTERATIONS IN THE SWI\/SNF COMPLEX: THE TILTS STUDY<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 1081914,72. 2022-2025. PI: Mart\u00edn Liberal, Juan.<\/p>\n 20MAR001. Molecular analysis of the metastatic process in developmental tumors. Fundaci\u00f3 TV3<\/strong>. Budget: 300000. 2020-2023. PI: MARTINEZ TIRADO, OSCAR.<\/p>\n 19ACL231. ESTUDIO DE FASE 1B\/2 DE LY3200882 Y PEMBROLIZUMAB EN PACIENTES CON C\u00c1NCER AVANZADO<\/strong>. Budget: 267326,4. 2019- . PI: Mart\u00edn Liberal, Juan.<\/p>\n 2021-070-1. PROSPECTIVE COLLECTION OF DONOR TISSUE AND WHOLE BLOOD OR LEUKAPHERESIS PRODUCT FROM PATIENTS WITH SOLID TUMOURS TO ENABLE DEVELOPMENT OF METHODS FOR THE MANUFACTURING OF CLONAL NEOANTIGEN T CELL PRODUCTS (cNeT). ACHILLES THERAPEUTICS UK LIMITED<\/strong>. Budget: 220881,12. 2021- . PI: Mart\u00edn Liberal, Juan.<\/p>\n 20ACL101. A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH – 1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA. REGENERON PHARMACEUTICAL, INC<\/strong>. Budget: 203366,88. 2020- . PI: Mart\u00edn Liberal, Juan.<\/p>\n\t\t\t\t\tTransfer\u00e8ncia de tecnologia<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tPAT064-EPH2A APTAMER AND USES THEREOF Sarcoma Resum El grup de recerca en sarcomes, liderat per l\u00b4\u00d2scar Martinez-Tirado, \u00e9s un grup multidisciplinar amb els objectius principals d’ identificar nous marcadors metast\u00e0tics i aprofundir en el seu paper biol\u00f2gic en sarcomes del desenvolupament, i identificar nous objectius terap\u00e8utics i validar nous marcadors pron\u00f2stics i predictius en sarcomes, avaluant precl\u00ednicament nous components per […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"publishpress_future_action":{"enabled":false,"date":"2024-05-13 00:53:06","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/1807"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=1807"}],"version-history":[{"count":5,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/1807\/revisions"}],"predecessor-version":[{"id":24866,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/1807\/revisions\/24866"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=1807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nIP: Oscar Mart\u00ednez tirado
\nEP19382451\nLicense: EPH2A APTAMER AND USES THEREOF
\nPI: Dr. \u00d3scar Mart\u00ednez-Tirado\nSpin-off: Aptadel Therapeutics
\nPI: Dr. \u00d3scar Mart\u00ednez-Tirado\n\t\t\t\t\tM\u00e9s informaci\u00f3<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tDesenvolupament d’un nou model ortot\u00f2pic per estudiar la met\u00e0stasi del sarcoma
\nDescripci\u00f3 del metiloma del sarcoma d’Ewing\n\t\t\t\t\n\n\t\tMartinez Tirado, Oscar\n\t<\/h4>\n
\n\t\t\n\t\tomartinez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tInvestigadors principals\n\t<\/h2>\n\t\t\t\t
\n\n\t\tMartinez Tirado, Oscar\n\t<\/h4>\n
\n\t\t\n\t\tomartinez@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t
\n\n\t\tGarc\u00eda del Muro, Solans Xavier\n\t<\/h4>\n
\n\t\t\n\t\tgarciadelmuro@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tENLLA\u00c7OS RELACIONATS\n\t<\/h4>\n
\n\t\t\n\t\tFacebook\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\t@SRGIDIBELL\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\t@omt2007\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tEquip\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tCaps de grup\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es principals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es cl\u00ednics\/ques\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es postdoctorals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es predoctorals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tSuport cient\u00edfic\t\t\t\t<\/a>\n\t\t\t\t\t\tCaps de grup\n\t\t\t\t\t\t\t\t\t\t\t
\n
\n
\n
\n
\n
\n
\n\t\tNot\u00edcies relacionades\n\t<\/h2>\n\t\t\n\t\t\t\t<\/a>\n\t\t\tL’IDIBELL i la Universitat de Iowa desenvolupen una nova mol\u00e8cula per al tractament dirigit contra el c\u00e0ncer<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t30\/05\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tL’IDIBELL rep 1,2 milions d’euros en ajuts per impulsar la recerca cient\u00edfica i la seva transfer\u00e8ncia<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t10\/01\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tLa inhibici\u00f3 farmacol\u00f2gica d’una prote\u00efna redueix les met\u00e0stasis en models in vivo i in vitro de sarcoma d’Ewing<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t01\/04\/2022\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tLa spin-off sorgida de l’IDIBELL Aptadel seleccionada per formar part de BCN Health Booster<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t26\/11\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tUn nou algoritme classifica els tipus de sarcoma<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t02\/02\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tAptadel, nova spinoff de l’IDIBELL<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t22\/01\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL celebra el Kickoff Meeting dels projectes finan\u00e7ats per La Fundaci\u00f3 La Marat\u00f3 de TV3 2019<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t18\/11\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tEl grup de recerca en sarcoma de l’IDIBELL rebr\u00e0 una de les noves ajudes AECC Innova<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t10\/09\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIdentifiquen una prote\u00efna determinant per a la progressi\u00f3 tumoral i la met\u00e0stasi del c\u00e0ncer infantil Rabdomiosarcoma<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t29\/01\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tL’IDIBELL i la Fundaci\u00f3n Alba P\u00e9rez fan un nou pas endavant per desenvolupar un tractament per al sarcoma d’Ewing<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t03\/12\/2019\t\t\t\t\t\t\t\n\t\t\n\n","protected":false},"excerpt":{"rendered":"